Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Autoimmune diseases arise when the immune system attacks one or more of the body's normal constituents as if they were invaders. When the immune system fails to recognize "self" it may produce immune cells or antibodies (called autoantibodies) that target its own cells, tissues, and organs. Those attacks cause inflammation and tissue damage that lead to autoimmune disorders. Furthermore, autoimmune disorders can be difficult to recognize and diagnose. Autoimmune disorders affecting multiple organs can lead to highly variable signs and symptoms that can change in severity over time. Vague and slow to develop signs and symptoms may be present and can be misleading during diagnosis. According to the American autoimmune related diseases association, approximately 50 million Americans, 20 percent of the population or one in five people, suffer from autoimmune diseases. Moreover, the numbers are anticipated to increase over the projection period. The demand for improved and accurate diagnostic methods, along with the growing prevalence, is estimated to upsurge over the forecast period.
High incidence and large economic burden of autoimmune diseases, advancements in technology and increasing access to medical insurance in the US are the factors driving the autoimmune disease diagnosis market growth. However, high capital requirements and lack of appropriate & advanced healthcare infrastructure in developing regions are some factors hampering the growth of the market.
The autoimmune disease diagnosis market is segmented by product & services, disease type, diagnosis technique, end user and geography
On the basis of product & services, the autoimmune disease diagnosis market is segmented into consumables and assay kits, instruments and services. The consumables and assay kits segments dominated the market owing to the growing adoption of consumables and assay kits and bulk buying of these products.
On the basis of disease type, the autoimmune disease diagnosis market is bifurcated into systemic autoimmune disease and localized autoimmune disease. The systemic autoimmune disease segment is classified into rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis and others. Likewise, the localized autoimmune disease segment is classified into inflammatory bowel disease, type 1 diabetes and thyroid. The systemic autoimmune disease segment accounted for the largest market share, due to the increasing incidences of the systemic autoimmune disease.
The diagnosis technique studied in this report are immunofluorescence assays (IFA), enzyme-linked immunosorbent assay (ELISA), western blotting, dot blot, line blot, multiplex immunoassay, agglutination, double immune diffusion, counter immune-electrophoresis and others.
The end user of the autoimmune disease diagnosis market is segmented into clinical laboratories, hospitals and other end users. The clinical laboratories segment accounted for the largest market share owing to the rising number of clinics coupled with availability of instrument for diagnostics.
Geographically, the global autoimmune disease diagnosis market is diversified into North America, Europe, Asia-Pacific and rest of the world. The North America region dominated the autoimmune disease diagnosis market in the 2018, owing to increasing healthcare expenditure and increasing prevalence of autoimmune diseases in the region. However, Asia Pacific is projected to emerge as the most promising region during the forecast period, due to the increasing research funding.
The key companies operating in the market are Abbott Laboratories, Biomérieux, Bio-rad Laboratories, Euroimmun AG, F. Hoffmann-la Roche, Inova Diagnostics, Inc., Myriad Genetics, Siemens Healthineers, Inc., Thermo Fisher Scientific, Trinity Biotech, AESKU DIAGNOSTICS, SQI Diagnostics Inc, Hemagen Diagnostics Inc. and Quest Diagnostics. New product launches, mergers & acquisitions are the key strategies adopted by market players to ensure their growth in the market.
The autoimmune disease diagnosis market is segmented by product & services, disease type, diagnosis technique, end user and geography. On the basis of product & services, the autoimmune disease diagnosis market is segmented into consumables and assay kits, instruments and services. The consumables and assay kits segments dominated the market owing to the growing adoption of consumables and assay kits and bulk buying of these products.
On the basis of disease type, the autoimmune disease diagnosis market is bifurcated into systemic autoimmune disease and localized autoimmune disease. The systemic autoimmune disease segment is classified into rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis and others. Likewise, the localized autoimmune disease segment is classified into inflammatory bowel disease, type 1 diabetes and thyroid. The systemic autoimmune disease segment accounted for the largest market share, due to the increasing incidences of the systemic autoimmune disease.
The diagnosis technique studied in this report are immunofluorescence assays (IFA), enzyme-linked immunosorbent assay (ELISA), western blotting, dot blot, line blot, multiplex immunoassay, agglutination, double immune diffusion, counter immune-electrophoresis and others.
The end user of the autoimmune disease diagnosis market is segmented into clinical laboratories, hospitals and other end users. The clinical laboratories segment accounted for the largest market share owing to the rising number of clinics coupled with availability of instrument for diagnostics.
Geographically, the global autoimmune disease diagnosis market is diversified into North America, Europe, Asia-Pacific and rest of the world. The North America region dominated the autoimmune disease diagnosis market in the 2018, owing to increasing healthcare expenditure and increasing prevalence of autoimmune diseases in the region. However, Asia Pacific is projected to emerge as the most promising region during the forecast period, due to the increasing research funding.
Why to buy this report:
